In the case of virus production, process performance has to be improved at each
stage of production,starting with upstream processing (USP) with increasing virus
particle yields, CSVY and space-time yield (STY), continuing with purification
strategies with a minimum number of unit operations and high recovery, debot-
tlenecking and optimizing modular solutions for manufacturing [8]. For example,
one general goal of process intensification in USP is to achieve high cell con-
centrations right from the start of thawing the cell bank, thereby reducing the time
to reach the required cell concentrations at the final process scale with a minimum
of scale-up steps (Figure 6.1). Based on high cell concentrations being reached in
the final production vessel, overall virus titers and virus yields can be higher in
case the CSVY can be kept at least constant. In this chapter, we will focus on USP
and the related challenges with the aim to increase viral yields.
6.3
PARAMETERS FOR PROCESS COMPARISON AND EVALUATION
Before addressing advanced concepts for process optimization and intensification,
tools or parameters for an unbiased comparison of virus production platforms are
needed. Therefore, in Table 6.1, the most commonly used measured or calculated
parameters are introduced using IAV as an example.
Standard cell bank
1 mL
10-25 E06 cells/mL
Inoculum train
N
N-1
N-2
N-3
Classical cell expansion for batch process, 3-4 weeks
HCD cell bank
50-500 mL
50-100 E06 cells/mL
CRD
CRD
Seed train
Seed train
N-1
N-2
CRD
N
Production vessel
Production vessel
Intensified production process, <3 weeks
FIGURE 6.1 Comparison of a conventional seed train process with an intensified process
using high-cell density cell banking and perfusion. HCD: high cell density; CRD: cell re-
tention device. Production run (N: cell growth and virus production) and all scale-up runs (N-
1, N-2, etc.) that involve cell growth only. Standard cell banks typically use 1–2 mL cryo
flasks, whereas HCD cell banks use dedicated freezing bags with volumes up to 500 mL.
Created with BioRender.com
140
Bioprocessing of Viral Vaccines